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S U M M A R Y
Objectives: Although vitamin D is recognized as an important factor in bone health, its role in
osteoarticular infections is unclear. We hypothesized that low vitamin D (25-hydroxycholecalciferol)
levels are associated with a lower likelihood of treatment success in osteoarticular infections.
Methods: This was a retrospective cohort study of patients with orthopedic infections who had a 25-
hydroxycholecalciferol level drawn when their infection was diagnosed. Outcomes were determined at
early (3–6 months) and late (6 months) follow-up after completing intravenous antibiotics.
Results: We included 223 patients seen during an 11-month period with osteoarticular infections and
baseline 25-hydroxycholecalciferol levels. During the initial inpatient management of the infection,
hypovitaminosis D was identiﬁed and treated. The mean 25-hydroxycholecalciferol level was
23  14 ng/ml; 167 (75%) patients had levels <30 ng/ml. Overall, infection treatment success was 91%
(159/174) at early follow-up and 88% (145/164) at late follow-up. 25-Hydroxycholecalciferol baseline levels
were similar in those with and without successful clinical outcomes, both at early (25  15 vs. 21  9 ng/ml;
p = 0.3) and late follow-up (25  15 vs. 23  16 ng/ml; p = 0.6).
Conclusions: To our knowledge this is the ﬁrst report on hypovitaminosis D and its impact on outcomes
of osteoarticular infections. Hypovitaminosis D was frequent in this cohort. With vitamin D repletion,
there was no difference in treatment success whether patients had baseline hypovitaminosis or not.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Osteoarticular infections are a heterogeneous group of infec-
tions that can pose considerable management challenges.1,2
Despite aggressive surgery and antimicrobial use, treatment
may fail in up to 20% of cases.3,4 For prosthetic joint infections,
several studies have identiﬁed a longer duration of symptoms,
sinus tract formation, Staphylococcus aureus infection, and a
surgical approach inconsistent with expert recommendations as
risk factors for treatment failure.5–7 In osteomyelitis, Pseudomonas
infections, vancomycin treatment for staphylococcal infections (as
opposed to beta-lactams), peripheral vascular disease, and§ This work was presented in part at the European Conference for Clinical
Microbiology and Infectious Diseases (ECCMID), London, UK, 2012.
* Corresponding author at: Corresponding author. Tel.: +41 31 632 9992;
fax: +41 31 632 3176.
E-mail address: jonas.marschall@insel.ch (J. Marschall).
http://dx.doi.org/10.1016/j.ijid.2014.05.004
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).diabetes mellitus are associated with treatment failure.8,9 Addi-
tional factors such as the host’s immune competency may also be
relevant; however, few published data address this hypothesis.
Speciﬁc blood tests that gauge nutritional status have also been
shown to predict outcomes of orthopedic surgeries.10
Vitamin D, long known for its role in bone health, has more
recently been found to also have a role in innate immunity.11 The
underlying mechanisms of its anti-infective activity include
triggering the antimicrobial peptide cathelicidin, increasing
cytokines, stimulating macrophage proliferation, and up-regulat-
ing the vitamin D receptor expressed on macrophages.12 Studies
have sought to determine whether vitamin D deﬁciency predis-
poses to infection,13 and whether vitamin D supplementation can
impact clinical outcomes.14 Most of these studies have been
carried out in tuberculosis, inﬂuenza, and respiratory infections
and the data are conﬂicting.15 Interestingly, despite the role of
vitamin D in bone metabolism and its presumptive role in the
remodeling process following bone disease, no studies have
examined the impact of hypovitaminosis D in patients withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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patients with osteoarticular infections and if lower vitamin D
levels may be associated with an increased risk of treatment
failure.
In this study we sought to retrospectively compare treatment
outcomes of patients with hypovitaminosis D at the start of
treatment for their osteoarticular infections with those who were
vitamin D-sufﬁcient at baseline. Our hypothesis was that cure rates
for patients with bone and joint infections who had normal vitamin
D levels at baseline would be higher than those of patients with
low levels.
2. Subjects and methods
2.1. Study design
We conducted a retrospective cohort study of adult patients
with orthopedic infections who were admitted to Barnes-Jewish
Hospital (BJH), a 1250-bed university-afﬁliated teaching hospital
in St. Louis, Missouri. All patients in the cohort were diagnosed
with osteomyelitis and/or septic arthritis (including prosthetic
joint infections) and had been seen by the Bone and Joint Infectious
Disease Consultation Service of the Division of Infectious Diseases,
Washington University School of Medicine, between October 1,
2009 and August 31, 2010. This service was established in 2009 to
provide dedicated consultation to the orthopedic services in the
hospital; although not all-inclusive, this service currently sees the
vast majority of orthopedic infections treated at BJH.
Patients were included in the study if there was clinical
evidence of an osteoarticular infection based on a combination of
criteria (intraoperative ﬁndings, pathology, and culture results),16
and if they had a documented baseline vitamin D (25-hydro-
xycholecalciferol) level that was drawn in the week before or at
initiation of antibiotic therapy. Patients aged <18 years were
excluded, as were patients who were seen by our service but had
either skin/soft tissue infections without evidence of osteoarticular
involvement or were determined to have a non-infectious
condition. As part of routine management, all patients with
hypovitaminosis D were supplemented with ergocalciferol 2000 IU
daily  950 mg elemental calcium twice daily for at least 6–10
weeks.17 Vitamin D levels were supposed to be repeated after 6–8
weeks in patients receiving supplements, and results were commu-
nicated with patients and their primary care physicians. We
determined outcomes during a follow-up time of at least 6 months
after completion of intravenous antibiotic treatment for all patients.
The lack of pre-existing data in the literature on the prevalence of
hypovitaminosis D in this population prevented us from conducting
sample size calculations.
The study was approved by the Washington University Human
Research Protection Ofﬁce with a waiver of informed consent due
to low risk to the enrolled individuals.
2.2. Data collection
The research subjects’ medical records were screened (by JL and
two data abstractors) using a standardized data collection tool.
Information regarding demographics, medical history, comorbid-
ities, clinical presentation, laboratory data, radiology ﬁndings,
surgical and medical management, and treatment outcomes was
collected for each subject from inpatient electronic records.
Follow-up tests of inﬂammatory markers (erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP)) and follow-up imaging
studies (if obtained) were gathered from the outpatient informa-
tion system, as were the clinical response and adverse events
(Clostridium difﬁcile infection, central venous catheter infection,
acute renal failure, elevated liver function tests, cytopenias, skinrashes, or other allergic reactions). We also evaluated potential risk
factors for treatment failure.
2.3. Endpoints and deﬁnition
The data from the subjects included in the study were entered
into a relational database from the standardized data collection
tool and then examined for the composite endpoint of ‘successful
treatment outcome’ at early (3–6 months) and late (6 months)
follow-up after completion of antibiotic therapy. Successful
treatment was deﬁned as the patient meeting all of the following
criteria: complete resolution of signs and symptoms of infection
(i.e., complete wound healing without drainage, redness, or
persistent pain), improvement in function, normalization of the
inﬂammatory markers ESR and CRP (when available), no repeat
surgery for osteomyelitis after discharge, no extension of intrave-
nous antibiotic treatment for >8 weeks, no readmission for
osteomyelitis within 6 months, and survival beyond 6 months. 25-
Hydroxycholecalciferol levels were deﬁned as follows: sufﬁcient at
30 ng/ml, insufﬁcient at <30 ng/ml and 20 ng/ml, and deﬁcient
at <20 ng/ml.18
2.4. Statistical analysis
Categorical variables were evaluated with the Chi-square test or
Fisher’s test, as appropriate, and continuous variables with the
Student’s t-test or Mann–Whitney U-test, as appropriate. A p-value
of <0.05 was considered to be statistically signiﬁcant. The main
objective was to determine the impact of baseline 25-hydro-
xycholecalciferol levels on the primary outcome; however, the
data were also evaluated based on other variables associated with
successful treatment, including hematogenous vs. contiguous
route of infection, presence of S. aureus infection, and presence
of diabetes as a comorbidity. Due to the small number of clinical
failures, we did not perform a multivariate analysis. The statistical
package IBM SPSS Statistics for Windows, version 21.0 (IBM Corp.,
Armonk, NY, USA) was used for the data analysis.
3. Results
A total of 363 patients were screened for inclusion in the study
and 223 (61.4%) were recruited based on the inclusion and
exclusion criteria. The mean  standard deviation (SD) age was
57  16 years. Patients were predominantly male (n = 124; 56%) and
white (n = 168; 75%) and had a median body mass index of 29 kg/m2
(range 16–60 kg/m2). The most common comorbidities were diabetes
mellitus (n = 75; 34%), osteoarthritis (n = 62; 28%), peripheral
vascular disease (n = 27; 12%), and chronic renal insufﬁciency
(n = 21; 9%); only a few patients had a malignancy (n = 6; 3%).
Thirteen (6%) carried a diagnosis of rheumatoid arthritis, and nine
(4%) were on immunosuppressive therapy. None of the patients were
known to be HIV-infected. There were 141 (63%) cases of osteomye-
litis, 55 (25%) patients with septic arthritis, and 27 (12%) had dual
diagnoses of osteomyelitis and septic arthritis. One hundred and
forty-one (63%) patients had hardware-associated infections. The
largest subgroups of the cohort were foot infections (n = 33; 15%), hip
prosthetic joint infections (n = 25; 11%), knee prosthetic joint
infections (n = 25; 11%), hardware-associated tibia/ﬁbula osteomye-
litis (n = 18; 8%), and hardware-associated vertebral osteomyelitis
(n = 14; 6%). Most infections were caused by S. aureus (n = 92; 41%) or
coagulase-negative staphylococci (n = 35; 16%) (including infections
where these pathogens were part of cultures that grew more than one
organism). There were 49/223 (22%) polymicrobial infections. Among
168/223 culture-positive infections, there were 119 (71%) mono-
microbial infections; 64/119 (54%) of these were due to S. aureus, 17/
119 (14%) to coagulase-negative staphylococci, 7/119 (6%) to
Figure 2. Mean baseline vitamin D serum levels (ng/ml) by subsequent clinical
outcomes at early (3–6 months) follow-up, in 174 patients with osteoarticular
infections. p-Value = 0.3. 8Outliers. *Extreme cases.
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enterococci. Fifty-ﬁve (25%) patients had culture-negative infections.
As part of the routine inpatient management, vitamin D levels
were obtained. Hypovitaminosis D was identiﬁed and treated. The
mean baseline 25-hydroxycholecalciferol level was 23  14 ng/ml.
One hundred and sixty-seven (75%) patients had levels <30 ng/ml
(either insufﬁcient or deﬁcient); 97 (44%) had levels <20 (deﬁcient
sensu stricto) (Figure 1).
Hypovitaminosis D was slightly more frequent in patients
admitted during fall/winter vs. those seen in spring/summer (98/
123 (80%) vs. 69/100 (69%); p = 0.07). Age, gender, and race were
not associated with vitamin D levels below 30 ng/ml (data not
shown). Overall, treatment success in evaluable patients was 91%
(159/174) at early follow-up and 88% (145/164) at late follow-up;
if loss to follow-up was considered a treatment failure, then 71%
(159/223) at early follow-up and 65% (145/223) at late follow-up
had treatment success. One hundred and fourteen patients out of
127 (90%) with vitamin D levels <30 ng/ml vs. 45/47 (96%) with
levels 30 ng/ml had successful outcomes at 3 months (p = 0.4),
and 103/117 (88%) vs. 42/47 (89%), respectively, had successful
outcomes at 6 months (p = 0.8). Limiting the comparison to
vitamin D deﬁciency sensu stricto, 64/70 (91%) with vitamin D
levels <20 ng/ml vs. 95/104 (91%) with levels 20 ng/ml had
successful outcomes at 3 months (p = 1.0), and 55/64 (86%) vs. 90/
100 (90%), respectively, had successful outcomes at 6 months
(p = 0.4). Vitamin D baseline levels were similar in those with or
without successful clinical outcomes, both at early (25  15 vs.
21  9 ng/ml; p = 0.3) (Figure 2) and late follow-up (25  15 vs.
23  16 ng/ml; p = 0.6) (Figure 3).
Follow-up levels were obtained for only 50 (22%) patients (after
at least 6–8 weeks), with a mean level of 32  14 ng/ml; many (21/
50; 42%) were still deﬁcient at that point. Follow-up vitamin D levels
of these 50 patients were not different between those with treatment
success and those with treatment failure, at either the 3–6 months
clinical follow-up (32  16 vs. 30  7 ng/ml; p = 0.8) or at the 6
months clinical follow-up (33  11 vs. 28  8 ng/ml; p = 0.4). If loss to
follow-up was considered a treatment failure, success rates at the
early follow-up point were similar in patients with replete vs.
deﬁcient/insufﬁcient follow-up vitamin D levels (22/29 (76%) vs. 17/
21 (81%); p = 0.7). However, at late follow-up there were fewer
successes in deﬁcient/insufﬁcient patients (12/21 (57%) vs. 25/29
(86%); p = 0.02).
We compared risk factors for clinical failure at early and late
follow-up time points. At early follow-up, a hematogenous
etiology of the infection was associated with failure (3/15 (20%)
failures vs. 5/159 (3%) successes; p = 0.02). S. aureus infections
(including polymicrobial staphylococcal infections) did not impact
outcomes at early follow-up (9/75 (12%) failures with S. aureus vs.25%
31%
44%
Vitamin D L evel
Suﬃcient (≥30  ng/ml)
Insuﬃcient  (<30  and  ≥20  ng/ml)
Deﬁcient  (< 20 ng/ml)
Figure 1. Distribution of baseline vitamin D levels in 223 patients with
osteoarticular infections.6/99 (6%) failures with other pathogens; p = 0.2). At late follow-up,
however, a hematogenous etiology was no longer associated with
failure (3/19 (16%) failures vs. 7/145 (5%) successes; p = 0.09), but S.
aureus infection was more likely to be associated with clinical
failure (13/67 (19%) failures with S. aureus vs. 6/97 (6%) with other
pathogens; p < 0.01). Age, gender, race, and comorbidities such as
diabetes mellitus (Table 1), renal insufﬁciency, and peripheral
vascular disease (data not shown) were not associated with clinical
failure.
All patients underwent some form of surgical debridement. For
23 (10%) patients, hardware was retained after debridement. Total
hardware explantation was done in 80 (36%) patients and
hardware was partially explanted in another 33 (15%) patients.
4. Discussion
Several studies have attempted to elicit risk factors for
treatment failure in bone and joint infections,5–9 but have not
focused on the immune system or vitamin D levels. Vitamin D isFigure 3. Mean baseline vitamin D serum levels (ng/ml) by subsequent clinical
outcomes at late (6 months) follow-up, in 164 patients with osteoarticular
infections. p-Value = 0.6. 8Outliers. *Extreme cases.
Table 1
Univariate analysis of risk factors for treatment failure at early (3–6 months)
follow-up in patients with osteoarticular infections (n = 174)a
Success
(n = 159)
Failure
(n = 15)
p-Value
Age, years 57.0  15.7 57.5  16.3 0.9
Gender, male 84 (53%) 11 (73%) 0.1
Race, white 125 (79%) 9 (60%) 0.1
Diabetes mellitus 107 (67%) 8 (53%) 0.3
Rheumatoid arthritis 12 (8%) 0 0.6
Baseline vitamin D level, ng/ml 25  15 21  9 0.3
Hematogenous etiology
of the osteoarticular infection
5 (3%) 3 (20%) 0.02
Staphylococcus aureus infection 66 (42%) 9 (60%) 0.2
SD, standard deviation.
a Results are presented as the mean  SD, or as the number (%).
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multiple roles in the innate and adaptive immune response to
infection. To date, treatment outcomes of orthopedic infections
have not been analyzed with regard to patient vitamin D serum
levels. We hypothesized that hypovitaminosis D may negatively
impact treatment outcomes. In this study, we did not ﬁnd an
association between low vitamin D serum levels at the start of
infection treatment and outcomes of orthopedic infections, when
vitamin D supplementation was provided along with antimicrobial
therapy.
Vitamin D is not only important for bone remodeling but also
has immunomodulatory properties that have been elucidated
recently.19 There are different functional aspects that result in its
anti-infective activity.12 Mobilizing neutrophil granulocytes and
upregulating the antimicrobial peptide cathelicidin may be the
most prominent pathways by which this occurs. However, a
systematic review published in 2009 concluded that vitamin D
supplementation for the prevention or treatment of infectious
diseases cannot be recommended due to a lack of evidence.15 More
recently, a number of publications have examined the value of
vitamin D supplementation in patients with HIV infection,20
pneumonia,21 and tuberculosis,22,23 without coming to clear
conclusions on its value in improving clinical outcomes in these
infections.
In our study, there was no detrimental effect of baseline
hypovitaminosis D on bone and joint infection outcomes, although
all of these patients were prescribed vitamin D repletion therapy
concomitantly with their antimicrobial therapy. Hypovitaminosis
D may still be a potentially modiﬁable risk factor for poor clinical
outcomes of osteoarticular infections if left untreated. There is no
published literature that describes the systematic detection of
vitamin D levels in patients with bone and joint infections and we
therefore cannot place our ﬁndings in a larger context. There have
been, however, case reports that have noted osteoarticular
infections in tuberculosis patients with very low vitamin D serum
levels.24 It should also be pointed out that there were more late
failures in the small group of patients who were still deﬁcient at
follow-up testing; this ﬁnding suggests that there may be an
impact of ongoing (or untreated) hypovitaminosis D on bone and
joint infection outcomes. This study also demonstrated that low
vitamin D levels were quite prevalent in this patient population.
We surmise that hypovitaminosis D is a treatable condition with a
possible impact on outcomes in patients with orthopedic infec-
tions.
Even though there is insufﬁcient evidence to support screening
for vitamin D deﬁciency in all types of infections, patients at risk for
orthopedic infections have many traditional risk factors for low
vitamin D levels. Vitamin D-deﬁcient patients with orthopedic
infections may beneﬁt from improved bone remodeling and bone
structure and/or immune support if their low vitamin D levels arecorrected with replacement therapy. The 2011 guidelines for
evaluating, treating, and preventing hypovitaminosis D by the US
Endocrine Society, however, do not speciﬁcally address patients
with bone and joint infections.25 The notion that hypovitaminosis
D may affect large proportions of hospitalized patients is,
nevertheless, not new, and has been documented both for
medical26 and surgical patients.27
The small number of treatment failures that were observed in
our study (9% at early and 12% at late follow-up) prevented us from
conducting a multivariate analysis of risk factors for clinical failure.
Similar to previous studies, S. aureus infection was associated with
clinical treatment failures.5 Previous studies have shown that
outcomes not only depend on the virulence of speciﬁc pathogens,
but also that they can be correlated with the duration of symptoms
before treatment is initiated, whether there is sinus tract
formation, and the type of surgical approach chosen. We did not
collect this information because it was not the main objective of
our study. Recently, another group reported that prosthetic joint
infections are more likely to result in poor outcomes if the affected
patients are potentially immunocompromised (which included
rheumatoid arthritis, diabetes mellitus, renal insufﬁciency, and
malignancy).28 There was no association between diagnosis of
rheumatoid arthritis or diabetes mellitus and clinical failure in our
study. Why the hematogenous development of an infection was
more likely to result in failure at the early follow-up time is
unclear. A potential explanation could be that the focus of infection
persisted and therefore gave rise to infection recurrence.
Limitations of our study include the retrospective cohort design
and the fact that no multivariate analysis of outcomes could be
performed due to the small number of treatment failures. Patients
were not included if vitamin D testing was missed; this could have
introduced a selection bias. There are no standard diagnostic
criteria for orthopedic infections, which could have led us to
include patients with ‘culture-negative’, non-infectious orthopedic
problems.29 The retrospective nature of the study also prevented
us from tracking adherence to vitamin D supplementation. Lastly,
because vitamin D supplementation was given to all deﬁcient/
insufﬁcient patients, we cannot discern what effect untreated
hypovitaminosis D would have had on outcomes.
In conclusion, we believe this to be the ﬁrst report on
hypovitaminosis D and its impact on outcomes of osteoarticular
infections. Hypovitaminosis D was frequent in this patient cohort.
There was no difference in treatment success at early or late
follow-up depending on baseline vitamin D levels as long as
vitamin D supplementation was given to those with vitamin D
deﬁciency. It is currently unresolved whether vitamin D has a
speciﬁc role in the management of bone and joint infections; this
could be tested in a randomized trial. Clinicians should continue to
monitor high risk patients for hypovitaminosis D as supplementa-
tion has beneﬁcial effects on bone health.
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